Newly Listed NewAmsterdam Pharma Touts Encouraging Data From High Cholesterol Treatment
Newly Listed NewAmsterdam Pharma Touts Encouraging Data From High Cholesterol Treatment
新上市的新阿姆斯特丹製藥公司吹捧鼓勵高膽固醇治療數據
- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced topline results from ROSE2 Phase 2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy.
- NewAmsterdam is now selecting a formulated fixed-dose combination tablet of obicetrapib plus ezetimibe, a non-statin oral LDL-lowering therapy, to be tested in a definitive bioequivalence and a Phase 3 safety & efficacy trial.
- The primary efficacy endpoint for the percent change from Day 1 to Day 84 in LDL-C for the combination treatment group compared to the placebo group was met.
- Patients treated with the combination of obicetrapib and ezetimibe achieved a median reduction in LDL-C of 59% compared to patients treated with a placebo, who achieved a median reduction in LDL-C of 6%.
- Overall, the obicetrapib combo therapy was well-tolerated, with a safety profile comparable to a placebo.
- In November 2022, NewAmsterdam Pharma debuted a public company via a SPAC deal with Frazier Lifesciences Acquisition Corporation.
- After the transaction, the company held a cash balance of approximately $490 million, which it believes will be sufficient to fund operations through 2026.
- Price Action: NAMS shares are trading lower by 2.25% at $9.99 on the last check Tuesday.
- 新阿姆斯特丹製藥公司 N.V. (NASDAQ: NAMS) 公佈 ROSE2 第二期試驗的頂線結果，以結合巴西曲比與以西咪比作為高強度他汀類藥物治療的輔助品進行評估。
- 新阿姆斯特丹目前正在選擇一種配方的固定劑量組合片劑，其中包含了 obicetrapib 和 ezetimibe，這是一種非他汀類藥物口服低密度脂蛋白治療，並在確定的生物等效性和 3 期安全與有效性試驗中進行測試。
- 與安慰劑組相比，LDL-C 組合治療組的第 1 天至第 84 天的百分比變化的主要療效終點得到了滿足。
- 與使用安慰劑治療的患者相比，使用安慰劑治療的患者與安慰劑治療的患者相比，LDL-C 的中位數降低了 6％，LDL-C 的中位數降低了 6％。
- 總體而言，obicetrapib 組合治療具有良好的耐受性，其安全性可與安慰劑相媲美。
- 2022 年 11 月，新阿姆斯特丹製藥公司通過 SPAC 協議首次亮相一家上市公司 弗雷澤生命收購公司。
- 交易完成後，該公司持有約 4.90 億美元的現金餘額，相信該結餘將足以為 2026 年的運營提供資金。
- 價格行動： 上次檢查週二，NAMS 股價下跌 2.25%，價格為 9.99 美元。